Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-11-29
2004-08-31
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S026000
Reexamination Certificate
active
06784202
ABSTRACT:
FIELD OF THE INVENTION
This invention pertains to therapeutically active cubane derivatives, a method for preparing the same, pharmaceutical compositions comprising the compounds and a method of treating diseases of the Central Nervous System (CNS) therewith.
BACKGROUND OF THE INVENTION
The acidic amino acid L-Glutamate is recognized as the major excitatory neurotransmitter in the CNS. The receptors that respond to L-Glutamate are called excitatory amino acid receptors. The excitatory amino acid receptors are thus of great physiological importance, playing a role in a variety of physiological processes, such as long-term potentiation (learning and memory), the development of synaptic plasticity, motor control, respiratory and cardiovascular regulation, and sensory perception.
Excitatory amino acid receptors are classified into two general types and both are activated by L-Glutamic acid and its analogs. Receptors activated by L-Glutamic acid that are directly coupled to the opening of cation channels in the cell membrane of the neurons are termed “ionotropic.” This type of receptor has been subdivided into at least three subtypes, which are defined by the depolarizing actions of the selective agonists N-Methyl-D-aspartate (NMDA), &agr;-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), and Kainic acid (KA).
The second general type of receptor is the G-protein or second messenger-linked “metabotropic” excitatory amino acid receptor. This second type is coupled to multiple second messenger systems that lead to enhanced phosphoinositide hydrolysis, activation of phospholipase D, increases or decreases in cAMP formation, and changes in ion channel function (Schoepp and Conn,
Trends in Pharmacological Science,
14:13, 1993). Both types of receptors appear not only to mediate normal synaptic transmission along excitatory pathways but also to participate in the modification of synaptic connections during development and throughout life.
So far eight different clones of the G-protein-coupled metabotropic glutamate receptors (mGluRs) have been identified (Knopfel et al., 1995,
J. Med Chem.,
38, 1417-1426). These receptors function to modulate the presynaptic release of L-Glutamate, and the postsynaptic sensitivity of the neuronal cell to L-Glutamate excitation. Based on pharmacology, sequence homology and the signal transduction pathway that they activate, the mGluRs have been subclassified into three groups. The mGluR1 and mGluR5 receptors form group 1. They are coupled to hydrolysis of phosphatidylinositol (PI) and are selectively activated by (RS)-3,5-dihydroxyphenylglycine (Brabet et al.,
Neuropharmacology,
34, 895-903, 1995). Group II comprises mGluR
2
and mGluR
3
receptors. They are negatively coupled to adenylate cyclase and are selectively activated by (2S,1′R,2′R,3′R)-2-(2,3-dicarboxycyclopropyl)glycine (DCG-IV; Hayashi et al.,
Nature,
366, 687-690, 1993). Finally, the mGluR
4
, mGluR
6
, mGluR
7
and mGluR
8
receptors belong to group III. They are also negatively coupled to adenylate cyclase and are selectively activated by (L)-2-amino-4phosphonobutyric acid (L-AP4; Knopfel et al., 1995,
J. Med. Chem.,
38, 1417-1426).
Agonists and antagonists of these receptors are believed useful for the treatment of acute and chronic neurodegenerative conditions, and as antipsychotic, anticonvulsant, analgesic, anxiolytic, antidepressant, and anti-emetic agents. Antagonists and agonists of neural receptors are classified as selective for a particular receptor or receptor subtype, or as non-selective. Antagonists may also be classified as competitive or non-competitive. While competitive and non-competitive antagonists act on the receptors in a different manner to produce similar results, selectivity is based upon the observations that some antagonists exhibit high levels of activity at a single receptor type, and little or no activity at other receptors. In the case of receptor-specific diseases and conditions, the selective agonists and antagonists are of the most value.
Compounds such as L-Glutamic acid, Quisqualic acid and Ibotenic acid are known to act as non-selective agonists on the mGluRs, while selective ionotropic glutamate receptor agonists such as NMDA, AMPA and Kainic acid have little effect on these receptors. Recently a few compounds without activity at the ionotropic glutamate receptors but with activity at the metabotropic receptors have been identified. These include trans-ACPD (trans (1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid), the partial agonist L-AP3 (L-2-amino-3-phosphonopropionic acid; Palmer, E., Monaghan, D. T. and Cotman, C. W.
Eur. J. Pharmacol.
166, 585-587, 1989; Desai, M. A. and Conn, P. J.
Neuroscience Lett.
109, 157-162, 1990; Schoepp, D. D. et al.,
J Neurochemistry.
56, 1789-1796, 1991; Schoepp D. D. and Johnson B. G.
J. Neurochemistry
53, 1865-1613, 1989), L-AP4 (L-2-amino-4-phosphonobutyric acid) which is an agonist at the mGluR
4
receptor (Thomsen C. et al.,
Eur. J. Pharmacol.
227, 361-362, 1992) and some of the isomers of CCG (2-(carboxycyclopropyl)glycines) especially L-CCG-I and L-CCG-II (Hayashi, Y. et al.,
Br. J Pharmacol.
107, 539-543, 1992).
Very few selective antagonists at the mGluRs have been reported. However some phenylglycine derivatives, S-4CPG (S-4carboxyphenylglycine), S-4C3HPG (S-4-carboxy-3-hydroxyphenylglycine) and S-MCPG (S-&agr;-methyl-4-carboxyphenylglycine) have been reported to antagonize trans-ACPD-stimulated phosphoinositide hydrolysis and thus possibly act as antagonists at mGluR
1
and mGluR
5
subtypes (Thomsen, C. and Suzdak, P,
Eur. J. Pharmacol.
245, 299, 1993).
Research directed towards mGluRs is beginning to show that mGluRs may be implicated in a number of normal as well as pathological mechanisms in the brain and spinal cord. For example, activation of these receptors on neurons can: influence levels of alertness, attention and cognition; protect nerve cells from excitotoxic damage resulting from ischemia, hypoglycemia and anoxia; modulate the level of neuronal excitation; influence central mechanisms involved in controlling movement; reduce sensitivity to pain; reduce levels of anxiety.
The use of compounds active at the mGluRs for the treatment of epilepsy is corroborated by investigations of the influence of trans-ACPD on the formation of convulsions (Sacaan and Schoepp,
Neuroscience Lett.
139, 77, 1992) and that phosphoinositide hydrolysis mediated via mGluR is increased after kindling experiments in rats (Akiyama et al.
Brain Res.
569, 71, 1992). Trans-ACPD has been shown to increase release of dopamine in the rat brain, which indicates that compounds acting on the mGluRs might be usable for the treatment of Parkinson's disease and Huntington's Chorea (Sacaan et al.,
J. Neurochemistry
59, 245, 1992).
Trans-ACPD has also been shown to be a neuroprotective agent in a medial cerebral artery occlusion (MCAO) model in mice(Chiamulera et al.
Eur. J. Pharmacol.
215, 353, 1992), and it has been shown to inhibit NMDA-induced neurotoxicity in nerve cell cultures (Koh et al.,
Proc. Natl. Acad. Sci. USA
88, 9431, 1991). The mGluR-active compounds are also implicated in the treatment of pain. This is proved by the fact that antagonists at the metabotropic glutamate receptors antagonize sensory synaptic response to noxious stimuli of thalamic neurons (Eaton, S. A. et al.,
Eur. J. Neuroscience,
5, 186, 1993).
The use of compounds active at the mGluRs for treatment of neurological diseases such as senile dementia have also been indicated by the findings of Zheng and Gallagher (
Neuron
9, 163, 1992) and Bashir et al. (
Nature
363, 347, 1993) who demonstrated that activation of mGluRs is necessary for the induction of long-term potentiation (LTP) in nerve cells (septal nucleus, hippocampus) and the finding that long-term depression is induced after activation of metabotropic glutamate receptors in cerebellar granule cells (Linden et al.
Neuron
7, 81, 1991).
Thus compounds that demonstrate either activating or inhibiting activity at mGluRs have thera
Curry Kenneth
Pajouhesh Hassan
Anderson Rebecca
McKane Joseph K.
Meyer Jerald L.
Nath Gary M.
Nath & Associates PLLC
LandOfFree
Cubane derivatives as metabotropic glutamate receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cubane derivatives as metabotropic glutamate receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cubane derivatives as metabotropic glutamate receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3329994